| Outcome | Probability | Yes Bid | Yes Ask | 24h Change | Volume | |
|---|---|---|---|---|---|---|
| Before 2033 | 0% | 0¢ | 0¢ | — | $0 | Trade → |
This prediction market asks whether the U.S. Food and Drug Administration will approve a therapy described as a cure for Type 1 diabetes before 2033. The outcome matters because an approved cure would change patient care, long-term health outcomes, and commercial dynamics in diabetes treatment.
Type 1 diabetes is an autoimmune condition in which insulin-producing beta cells are destroyed, requiring lifelong insulin replacement; researchers have pursued immunotherapies, beta-cell replacement, and gene-based approaches for decades. In recent years, progress in stem-cell biology, gene editing, and immune modulation, plus regulatory pathways for regenerative medicine, have created plausible development pathways—but clinical efficacy, durable safety, and manufacturing scale remain major hurdles.
Prediction market prices aggregate traders' views about scientific, clinical, and regulatory likelihoods before the 2033 deadline; they are snapshots of market consensus and not clinical advice.
For this event, a result that would plausibly be counted as a cure is an FDA approval of a product explicitly intended to reverse or eliminate the disease process (for example restoring endogenous insulin production and eliminating the need for exogenous insulin). If an approval is ambiguous or labeled differently, final resolution may depend on the market platform's official rules.
Leading candidates include stem-cell–derived beta-cell replacement or encapsulated islet transplants, gene therapies that restore beta-cell function or protect cells from autoimmune attack, and combination approaches that pair immune tolerance induction with cell replacement.
Expedited FDA programs such as Regenerative Medicine Advanced Therapy (RMAT), Breakthrough Therapy, Fast Track, or Accelerated Approval can shorten timelines by enabling earlier interactions, surrogate endpoints, or conditional approvals, but they still require evidence of benefit and follow-up confirmatory data.
Trials demonstrating durable insulin independence, sustained improvement in C-peptide (endogenous insulin marker), and acceptable safety over multi-year follow-up will be most persuasive; reliance on surrogate endpoints can enable faster decisions but typically requires post-approval confirmation.
Relevant precedents include approvals of cell and gene therapies in other disease areas and prior FDA usage of accelerated/regenerative pathways—these show both that novel biologic cures can be approved and that development and post-market obligations often take many years.